1h Free Analyst Time
Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Oxford BioMedica Plc (Oxford Biomedica) is a biopharmaceutical company involved in the development and commercialization of gene-based medicines. It provides LentiVector, a sector leading lentiviral vector delivery platform. Based on this platform the company has developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology, central nervous system (CNS), and other therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in Oxfordshire, the UK. Oxford BioMedica is headquartered in Oxford, the UK.Oxford BioMedica Plc Key Recent Developments
- May 15, 2023: Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
- Apr 26, 2023: Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
- Apr 26, 2023: Oxford Biomedica PLC Board Appointment
- Apr 25, 2023: Oxford BioMedica : Preliminary results for the year ended 31 December 2022
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Proteome Sciences Plc
- Phynova Group Ltd
- Agenus Inc
- Vernalis R&D Ltd
- Alliance Pharma Plc
- Summit Therapeutics Inc
- Silence Therapeutics Plc
- Almac Group Ltd
- Transgene SA
- Vernalis R&D Ltd
- Alliance Pharma Plc
- Summit Therapeutics Inc
- Silence Therapeutics Plc
- Almac Group Ltd
- Phynova Group Ltd
- Agenus Inc
- Transgene SA
- Proteome Sciences Plc